Groupe d'Etude en Oncologie du Quebec

Titre	Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor
Protocole ID	GSK 208750
ClinicalTrials.gov ID	NCT03391778
Type(s) de cancer	Autre
Phase	Autres
Institution	CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX 5415 boul. de l'Assomption, Montréal, QC, H1T2M4
Ville	Montréal
Investigateur(trice) principal(e)	Dr Jonathan Noujaim
Coordonnateur(trice)	Olivier Cormier 514-252-3400 poste 5966
Statut	Actif en recrutement
Critètes d'éligibilité	Subjects who have received at least one dose of GSK3377794 in the interventional study. Subjects who have either completed the interventional study or have withdrawn from it. Male or Female subjects. Capable of giving signed informed consent prior to the study participation.
Critètes d'exclusion	None

Groupe d'étude en oncologie du Québec